Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
All articles — 31945 total
CI closed September's first trading day at $283.06, up 2.5% on the session and 1.3% on the week — a tidy recovery from July's post-earnings bruise, but one that hasn't shaken the short sellers who rebuilt positions…
Allogene Therapeutics enters September with an unusual structural tension: Pfizer holds a 13D activist stake in the company while short sellers remain deeply dug in at more than a quarter of the free float. The short…
NIO heads into its September 4 earnings release with the lending market at a 52-week extreme, two high-profile analyst cuts landed the same morning, and the stock trading at $4.06 — down 17% over the past month. The…
Comstock Resources has delivered its sharpest weekly gain in months, jumping 13% to $16.02 and up 11% on Tuesday alone — yet the Street is only now beginning to acknowledge the move, with a flurry of target-price…
OPRA heads into its September 3 earnings report with short sellers adding exposure quietly over the past month, a dominant Chinese parent holding the float hostage, and an options market that has turned notably more…
Crinetics Pharmaceuticals is a stock that has effectively stopped trading on fundamentals — every metric now orbits a single fact: Vertex Pharmaceuticals has agreed to acquire the company for $85 per share in cash, a…
XLC heads into the first week of September with the bear position that rebuilt so aggressively in late August now holding firm — and the price tape confirming the skeptics, at least for the moment. The short position…
Scholar Rock heads into September with a notable tension at its core: a strong one-month rally of 18% sits alongside short interest that has quietly ground higher, an activist on the register, and a pair of…
Ascendis Pharma reports Q3 results on September 4 with the Street firmly bullish but modestly dialling back expectations — while short interest has quietly built to its highest level in six weeks. The analyst picture…
SELLAS Life Sciences Group enters September with one of the most charged short-selling setups in small-cap biotech — 41% of the free float sold short, essentially no shares left to borrow, and a stock that has surged…
Telix Pharmaceuticals enters September with a stock down 5.5% on the week yet carrying a month-long gain of 7.5% — a split picture that captures the tug-of-war between improving fundamentals and a short book that…
VICI Properties heads into the final days of August with options traders growing noticeably more cautious — even as short sellers quietly retreat. The clearest signal this week is in options. The put/call ratio has…
MongoDB closes a remarkable two-week earnings cycle with the Street firmly in its corner — even as the stock pulls back 4.2% on September 1 to $434.21, the analyst response to its second August print has been the most…
IperionX enters September with a curious split: the stock is edging higher, but short sellers are quietly adding to what is already a heavy bearish position. Short interest is the dominant story here. Bears hold 10.8%…
Zai Lab heads into September with a curious split: short sellers are rebuilding positions at the fastest pace in months, yet options traders have abruptly abandoned the defensiveness that defined the past two…
Solaris Energy Infrastructure heads into September with a curious split: shorts are quietly covering, analysts are clustered well above the current price, but the stock just shed 6% in a week while most peers rallied…
YEXT enters its September 4 earnings report carrying an unusual ownership story — two activist investors on the 13D register, a Street that just nudged its target higher, and options positioning that has normalised…
Brighthouse Financial presents a split picture heading into September — a modest weekly bounce on the surface, a 14% monthly selloff underneath it, and short sellers who added aggressively through August but are now…
The Trade Desk enters September with short sellers still firmly in control — yet the stock managed a 4% recovery this week, creating a rare moment of tension between a crowded short book and a tentative price…
Johnson Controls International heads into September with a clear tension: the stock has given back 5% over the past month to $139.25, yet the Street keeps lifting its sights. Morgan Stanley's Chris Snyder moved this…
